Schenk D - Search Results

1

Introduction to the special issue of Experimental Neurology on Alzheimer's disease.

Schenk D. Schenk D. Exp Neurol. 2010 Jun;223(2):251. doi: 10.1016/j.expneurol.2010.03.012. Epub 2010 Mar 25. Exp Neurol. 2010. PMID: 20346942 No abstract available.

2

What do people at risk for Alzheimer disease think about surrogate consent for research?

Schenk DB, Gilman S. Schenk DB, et al. Neurology. 2006 Jun 13;66(11):1785-6. doi: 10.1212/01.wnl.0000230558.24386.cd. Neurology. 2006. PMID: 16769971 No abstract available.

3

The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects.

Benowitz LI, Rodriguez W, Paskevich P, Mufson EJ, Schenk D, Neve RL. Benowitz LI, et al. Among authors: schenk d. Exp Neurol. 1989 Dec;106(3):237-50. doi: 10.1016/0014-4886(89)90156-8. Exp Neurol. 1989. PMID: 2591522

4

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.

Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Masliah E, et al. Among authors: schenk d. Neurology. 2005 Jan 11;64(1):129-31. doi: 10.1212/01.WNL.0000148590.39911.DF. Neurology. 2005. PMID: 15642916

5

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators. Salloway S, et al. Among authors: schenk d. Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18. Neurology. 2009. PMID: 19923550 Free PMC article. Clinical Trial.

6

Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer's disease.

Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D. Hyman BT, et al. Among authors: schenk d. J Neuropathol Exp Neurol. 1992 Jan;51(1):76-83. doi: 10.1097/00005072-199201000-00009. J Neuropathol Exp Neurol. 1992. PMID: 1740675

7

Abeta species removal after abeta42 immunization.

Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Nicoll JA, et al. Among authors: schenk d. J Neuropathol Exp Neurol. 2006 Nov;65(11):1040-8. doi: 10.1097/01.jnen.0000240466.10758.ce. J Neuropathol Exp Neurol. 2006. PMID: 17086100

8

beta-peptide immunization: a possible new treatment for Alzheimer disease.

Schenk DB, Seubert P, Lieberburg I, Wallace J. Schenk DB, et al. Arch Neurol. 2000 Jul;57(7):934-6. doi: 10.1001/archneur.57.7.934. Arch Neurol. 2000. PMID: 10891974 Review. No abstract available.

9

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P. Lee M, et al. Among authors: schenk d. Ann Neurol. 2005 Sep;58(3):430-5. doi: 10.1002/ana.20592. Ann Neurol. 2005. PMID: 16130106

10

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. Rinne JO, et al. Among authors: schenk d. Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26. Lancet Neurol. 2010. PMID: 20189881 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters